Stock Analysis on Net

Pfizer Inc. (NYSE:PFE) 

Common Stock Valuation Ratios (Price Multiples)
Quarterly Data

Microsoft Excel

Historical Valuation Ratios (Summary)

Pfizer Inc., historical price multiples (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Price to earnings (P/E) 19.83 14.06 13.09 17.22 18.42 37.00 73.42 16.60 9.42 7.44 7.58 8.81 9.56 11.11
Price to operating profit (P/OP) 10.82 10.07 9.49 11.27 11.92 27.24 121.63 17.49 9.17 6.74 6.80 7.82 9.11 11.49
Price to sales (P/S) 2.46 2.20 2.20 2.17 2.32 2.60 3.00 2.86 2.61 2.51 2.58 2.32 2.37 2.63 2.77 3.00
Price to book value (P/BV) 1.78 1.49 1.59 1.50 1.68 1.70 1.92 1.74 1.75 1.80 2.04 2.14 2.48 2.83 3.21 3.37

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).


Over the observed period, the common stock valuation ratios exhibited distinct trends. Generally, ratios decreased from April 2022 through the end of 2022, followed by fluctuations and, in some cases, increases through the subsequent quarters. A significant outlier occurred in late 2022 and early 2023 for Price to Operating Profit and Price to Earnings, which then normalized. The latter half of the period, from late 2023 through mid-2025, shows a degree of stabilization, though with continued variability.

Price to Earnings (P/E)
The Price to Earnings ratio demonstrated a consistent decline from 11.11 in April 2022 to a low of 7.58 in December 2022. It then increased to 9.42 in July 2023 before spiking dramatically to 73.42 in December 2023. Following this peak, the ratio decreased substantially, settling around 13.09 to 19.83 in the final observed periods. This suggests a period of significant earnings growth followed by a correction or change in market perception.
Price to Operating Profit (P/OP)
Similar to the P/E ratio, Price to Operating Profit decreased from April 2022 to December 2022, reaching 6.80. A substantial increase was observed in December 2023, reaching 121.63, mirroring the trend in P/E. The ratio then declined, stabilizing between approximately 9.49 and 17.49 in the later quarters. The parallel movement with P/E suggests a strong correlation between earnings and operating profit perception.
Price to Sales (P/S)
The Price to Sales ratio exhibited a more moderate trend. It decreased from 3.00 in April 2022 to 2.37 in December 2022, then fluctuated between 2.32 and 2.61 through much of 2023 and 2024. A slight upward trend is visible in the most recent periods, reaching 2.46 in December 2025. This ratio demonstrates greater stability compared to the earnings-based ratios.
Price to Book Value (P/BV)
The Price to Book Value ratio showed a consistent downward trend from 3.37 in April 2022 to a low of 1.74 in April 2023. It then experienced some volatility, with a slight increase to 1.92 in June 2024, before decreasing again to 1.49 in September 2025, and finally increasing to 1.78 in December 2025. This suggests a changing perception of the company’s asset value relative to its market price.

In summary, the valuation ratios indicate a period of dynamic change, particularly in late 2023, followed by a degree of stabilization. The significant spikes in P/E and P/OP ratios warrant further investigation to understand the underlying drivers. The P/S and P/BV ratios demonstrate more moderate and consistent trends, suggesting a relatively stable valuation based on sales and book value.

AI Ask an analyst for more


Price to Earnings (P/E)

Pfizer Inc., historical P/E calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
No. shares of common stock outstanding1 5,686,267,431 5,685,707,552 5,685,550,500 5,685,365,587 5,667,340,414 5,666,990,035 5,666,695,064 5,666,592,898 5,646,778,425 5,646,413,292 5,645,959,570 5,645,307,020 5,619,074,621 5,613,314,537 5,612,351,809 5,610,895,801
Selected Financial Data (US$)
Net income (loss) attributable to Pfizer Inc. common shareholders (in millions) (1,647) 3,541 2,910 2,967 410 4,465 41 3,115 (3,369) (2,382) 2,327 5,543 4,994 8,608 9,906 7,864
Earnings per share (EPS)2 1.37 1.73 1.89 1.39 1.42 0.75 -0.46 -0.05 0.38 1.86 3.80 5.15 5.58 5.30 5.22 4.45
Share price1, 3 27.10 24.30 24.75 23.87 26.10 27.76 29.74 28.27 27.55 30.82 35.84 38.30 42.30 46.72 49.95 49.45
Valuation Ratio
P/E ratio4 19.83 14.06 13.09 17.22 18.42 37.00 73.42 16.60 9.42 7.44 7.58 8.81 9.56 11.11
Benchmarks
P/E Ratio, Competitors5
AbbVie Inc. 94.06 159.78 92.57 77.73 79.59 69.16 62.04 48.26 63.84 38.27 30.55 34.43 22.62 19.16 19.44 21.64
Amgen Inc. 25.81 24.59 23.15 25.49 38.24 40.68 53.65 44.38 23.14 18.09 16.31 16.18 19.56 21.00 20.03 22.23
Bristol-Myers Squibb Co. 17.30 15.38 17.46 18.29 12.27 13.01 15.93 19.43 23.97 23.71 24.14 25.64
Danaher Corp. 40.93 44.52 39.84 36.51 38.12 48.49 45.39 42.59 39.09 24.76 29.99 25.00 25.65 26.65 32.73 32.15
Eli Lilly & Co. 47.45 43.36 43.95 67.76 77.63 96.05 109.42 120.94 135.24 110.43 76.21 65.16 50.08 55.53 51.05 45.29
Gilead Sciences Inc. 21.54 18.18 21.68 20.62 296.57 925.87 89.29 166.76 16.17 17.10 17.88 17.75 22.68 29.30 18.66 17.25
Johnson & Johnson 21.66 18.51 18.02 17.14 26.92 27.19 10.11 9.46 10.73 10.12 33.35 33.43 22.97 23.52 24.98 23.95
Merck & Co. Inc. 16.79 11.00 12.30 11.98 13.49 20.98 20.73 140.05 893.99 56.85 86.53 22.92 19.21 16.41 13.36 15.70
Regeneron Pharmaceuticals Inc. 18.19 15.03 13.29 13.65 17.76 19.79 27.88 26.78 25.99 22.35 19.48 19.77 19.68 14.98 11.67 9.15
Thermo Fisher Scientific Inc. 28.82 32.45 26.56 24.55 32.03 34.78 37.81 36.21 35.65 29.57 37.01 34.99 30.55 27.64 31.09 28.15
Vertex Pharmaceuticals Inc. 31.58 29.11 26.43 26.34 30.42 28.09 27.49 27.34 23.02 24.62 23.12 26.50

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Data adjusted for splits and stock dividends.

2 Q4 2025 Calculation
EPS = (Net income (loss) attributable to Pfizer Inc. common shareholdersQ4 2025 + Net income (loss) attributable to Pfizer Inc. common shareholdersQ3 2025 + Net income (loss) attributable to Pfizer Inc. common shareholdersQ2 2025 + Net income (loss) attributable to Pfizer Inc. common shareholdersQ1 2025) ÷ No. shares of common stock outstanding
= (-1,647,000,000 + 3,541,000,000 + 2,910,000,000 + 2,967,000,000) ÷ 5,686,267,431 = 1.37

3 Closing price as at the filing date of Pfizer Inc. Quarterly or Annual Report.

4 Q4 2025 Calculation
P/E ratio = Share price ÷ EPS
= 27.10 ÷ 1.37 = 19.83

5 Click competitor name to see calculations.


The price to earnings (P/E) ratio exhibited considerable fluctuation throughout the observed period. Initially, the ratio demonstrated a decreasing trend from April 2022 to December 2022, followed by significant volatility and then a general decline through the end of 2025.

Initial Decline (Apr 3, 2022 – Dec 31, 2022)
The P/E ratio decreased from 11.11 to 7.58 over this period. This decline occurred alongside a relatively stable share price and increasing earnings per share (EPS), suggesting that earnings growth was not sufficient to offset investor expectations or that the market anticipated future earnings deceleration. The most substantial decrease occurred between October 2022 and December 2022.
Volatility and Peak (Apr 2, 2023 – Dec 31, 2023)
Following the initial decline, the P/E ratio experienced significant volatility. It rose sharply to 73.42 by December 2023, driven by a substantial decrease in EPS from US$3.80 in July 2023 to US$0.38 in December 2023, while the share price experienced a more moderate decline. This indicates a considerable negative market reaction to the earnings decrease.
Subsequent Moderation and Decline (Mar 31, 2024 – Dec 31, 2025)
After the peak in December 2023, the P/E ratio generally trended downward, with fluctuations. The ratio decreased to 19.83 by December 2025. This period coincided with a recovery in EPS, although the share price also experienced some appreciation. The P/E ratio remained elevated compared to the levels observed in the first half of the period, but the extreme value seen in December 2023 diminished. Missing values for the P/E ratio in the first half of 2024 suggest either a lack of reported data or a calculation issue during those periods.

Overall, the P/E ratio’s movement suggests a dynamic relationship between share price and earnings. The initial decline indicated potential concerns about future growth, while the spike in late 2023 reflected a significant negative earnings surprise. The subsequent moderation suggests a partial recovery in investor sentiment as earnings began to improve.

AI Ask an analyst for more


Price to Operating Profit (P/OP)

Pfizer Inc., historical P/OP calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
No. shares of common stock outstanding1 5,686,267,431 5,685,707,552 5,685,550,500 5,685,365,587 5,667,340,414 5,666,990,035 5,666,695,064 5,666,592,898 5,646,778,425 5,646,413,292 5,645,959,570 5,645,307,020 5,619,074,621 5,613,314,537 5,612,351,809 5,610,895,801
Selected Financial Data (US$)
Operating income (loss) (in millions) 2,872 3,851 3,783 3,738 2,347 4,959 1,003 4,102 (4,289) (3,170) 2,194 6,544 4,381 8,943 12,219 9,401
Operating profit per share2 2.50 2.41 2.61 2.12 2.19 1.02 -0.42 -0.21 0.23 1.76 3.91 5.68 6.22 5.98 5.48 4.30
Share price1, 3 27.10 24.30 24.75 23.87 26.10 27.76 29.74 28.27 27.55 30.82 35.84 38.30 42.30 46.72 49.95 49.45
Valuation Ratio
P/OP ratio4 10.82 10.07 9.49 11.27 11.92 27.24 121.63 17.49 9.17 6.74 6.80 7.82 9.11 11.49
Benchmarks
P/OP Ratio, Competitors5
AbbVie Inc. 26.37 42.20 31.76 32.37 37.26 25.63 26.99 22.62 24.34 16.55 15.26 16.15 14.78 14.52 14.12 14.57
Amgen Inc. 21.92 19.86 18.71 20.31 21.55 27.68 27.12 23.97 19.69 15.45 13.71 14.25 13.40 14.89 14.08 15.88
Bristol-Myers Squibb Co. 12.20 10.25 11.07 13.65 13.53 14.14 16.24 17.09 18.29 17.79 18.62 20.32
Danaher Corp. 31.54 33.80 30.79 28.49 30.56 39.52 38.14 37.52 35.64 23.61 27.01 21.31 20.97 20.71 25.91 26.48
Eli Lilly & Co. 37.24 34.60 35.19 53.43 63.73 79.30 88.66 99.34 109.75 93.27 69.42 59.60 43.88 46.48 39.20 36.49
Gilead Sciences Inc. 18.29 14.06 17.00 14.96 85.65 143.05 36.80 51.26 12.05 12.16 11.57 11.21 14.21 16.27 11.02 10.78
Johnson & Johnson 22.95 19.83 19.04 17.74 18.20 18.65 17.54 16.96 17.78 15.69 18.91 18.26 17.62 19.64 20.45 21.06
Merck & Co. Inc. 14.44 9.67 10.57 10.37 11.60 18.67 18.41 75.94 138.56 33.75 44.67 18.53 15.55 13.85 11.72 14.29
Regeneron Pharmaceuticals Inc. 22.90 18.65 15.42 16.03 19.63 23.18 30.86 26.82 25.39 21.13 19.32 18.68 18.01 12.91 9.68 7.98
Thermo Fisher Scientific Inc. 24.94 28.40 23.62 21.64 27.65 29.74 32.66 31.40 31.16 25.59 31.55 29.54 25.30 21.43 23.99 21.84
Vertex Pharmaceuticals Inc. 29.92 26.79 24.50 25.25 28.74 25.14 23.33 22.03 17.75 19.41 18.11 22.13

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Data adjusted for splits and stock dividends.

2 Q4 2025 Calculation
Operating profit per share = (Operating income (loss)Q4 2025 + Operating income (loss)Q3 2025 + Operating income (loss)Q2 2025 + Operating income (loss)Q1 2025) ÷ No. shares of common stock outstanding
= (2,872,000,000 + 3,851,000,000 + 3,783,000,000 + 3,738,000,000) ÷ 5,686,267,431 = 2.50

3 Closing price as at the filing date of Pfizer Inc. Quarterly or Annual Report.

4 Q4 2025 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 27.10 ÷ 2.50 = 10.82

5 Click competitor name to see calculations.


The Price to Operating Profit (P/OP) ratio exhibited considerable fluctuation over the observed period. Initially, the ratio demonstrated a decreasing trend from April 2022 to December 2022, followed by significant volatility and then a stabilization towards the end of the period. A notable spike occurred in December 2022, followed by a return to more moderate levels.

Initial Decreasing Trend (Apr 3, 2022 – Dec 31, 2022)
From April 2022 through December 2022, the P/OP ratio decreased from 11.49 to 6.80. This decline suggests that the market valuation relative to operating profit was decreasing during this timeframe. The share price experienced a moderate decline during this period, while operating profit per share generally increased, contributing to the ratio’s downward movement.
Significant Volatility and Spike (Apr 2, 2023 – Dec 31, 2022)
The ratio experienced substantial volatility in early 2023, moving from 6.74 in April to 9.17 in July, then sharply decreasing to 17.49 in October, and culminating in a dramatic increase to 121.63 in December. This extreme spike in December 2022 coincided with a substantial decrease in operating profit per share (to 0.23), indicating a disproportionate impact on the ratio. The share price remained relatively stable during this period.
Stabilization and Recent Trends (Mar 31, 2024 – Jun 29, 2025)
Following the December 2022 peak, the P/OP ratio decreased to 27.24 by March 2024, then fluctuated between approximately 9.49 and 17.49 for the remainder of the observed period. The ratio ended at 10.82 in December 2025. This suggests a period of relative stabilization, although continued fluctuations were present. Operating profit per share generally increased during this period, while the share price showed modest changes.

The considerable variation in the P/OP ratio throughout the period suggests sensitivity to changes in both share price and, more significantly, operating profit per share. The December 2022 anomaly warrants further investigation to understand the underlying factors contributing to the extreme ratio value.

Missing Values
Values for the P/OP ratio are missing for several quarters, specifically between March 31, 2024 and December 31, 2024. This absence of information limits the ability to fully assess the trend during that period.

AI Ask an analyst for more


Price to Sales (P/S)

Pfizer Inc., historical P/S calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
No. shares of common stock outstanding1 5,686,267,431 5,685,707,552 5,685,550,500 5,685,365,587 5,667,340,414 5,666,990,035 5,666,695,064 5,666,592,898 5,646,778,425 5,646,413,292 5,645,959,570 5,645,307,020 5,619,074,621 5,613,314,537 5,612,351,809 5,610,895,801
Selected Financial Data (US$)
Revenues (in millions) 17,557 16,654 14,653 13,715 17,763 17,702 13,283 14,879 14,568 13,492 13,007 18,486 24,289 22,638 27,742 25,661
Sales per share2 11.01 11.04 11.23 10.99 11.23 10.66 9.92 9.87 10.55 12.27 13.89 16.50 17.86 17.79 18.05 16.47
Share price1, 3 27.10 24.30 24.75 23.87 26.10 27.76 29.74 28.27 27.55 30.82 35.84 38.30 42.30 46.72 49.95 49.45
Valuation Ratio
P/S ratio4 2.46 2.20 2.20 2.17 2.32 2.60 3.00 2.86 2.61 2.51 2.58 2.32 2.37 2.63 2.77 3.00
Benchmarks
P/S Ratio, Competitors5
AbbVie Inc. 6.50 6.40 5.97 5.68 6.04 6.38 6.02 5.32 5.72 4.52 4.74 4.60 4.61 4.44 4.28 4.76
Amgen Inc. 5.66 4.99 4.57 4.61 4.88 5.53 5.68 5.93 5.78 5.34 5.14 5.14 5.17 5.85 5.35 5.21
Bristol-Myers Squibb Co. 2.53 1.93 1.85 2.08 2.36 2.38 2.20 1.99 2.19 2.40 2.81 3.10 3.29 3.39 3.39 3.41
Danaher Corp. 6.02 6.43 5.66 5.77 6.23 7.95 8.10 7.90 7.76 5.63 6.77 5.76 5.79 5.66 6.59 6.68
Eli Lilly & Co. 15.03 13.44 11.39 15.36 18.25 19.67 20.64 20.66 20.77 17.18 16.78 13.38 10.96 11.46 9.99 9.47
Gilead Sciences Inc. 6.34 5.16 4.76 4.31 4.98 4.18 3.41 2.97 3.40 3.69 3.61 3.70 3.86 3.64 2.84 2.86
Johnson & Johnson 6.16 5.04 4.51 4.19 4.26 4.55 4.44 4.25 4.43 4.01 4.84 4.60 4.34 4.69 4.80 5.00
Merck & Co. Inc. 4.71 3.26 3.17 3.27 3.60 4.03 4.56 5.26 5.43 4.42 4.62 5.16 4.71 4.25 3.87 4.12
Regeneron Pharmaceuticals Inc. 5.71 4.83 4.17 4.36 5.52 6.65 8.93 7.89 7.84 6.81 6.61 6.69 7.01 5.87 4.66 4.40
Thermo Fisher Scientific Inc. 4.34 4.87 4.05 3.73 4.73 5.04 5.55 5.14 4.99 4.05 4.87 4.81 4.73 4.40 5.40 5.20
Vertex Pharmaceuticals Inc. 10.40 9.13 8.42 10.41 10.78 12.12 12.35 10.39 11.16 10.10 9.73 9.68 8.56 9.26 8.85 8.17

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Data adjusted for splits and stock dividends.

2 Q4 2025 Calculation
Sales per share = (RevenuesQ4 2025 + RevenuesQ3 2025 + RevenuesQ2 2025 + RevenuesQ1 2025) ÷ No. shares of common stock outstanding
= (17,557,000,000 + 16,654,000,000 + 14,653,000,000 + 13,715,000,000) ÷ 5,686,267,431 = 11.01

3 Closing price as at the filing date of Pfizer Inc. Quarterly or Annual Report.

4 Q4 2025 Calculation
P/S ratio = Share price ÷ Sales per share
= 27.10 ÷ 11.01 = 2.46

5 Click competitor name to see calculations.


The price-to-sales (P/S) ratio exhibited a generally declining trend over the observed period, punctuated by periods of stabilization and modest increases. Initial values indicated a P/S ratio of 3.00, which decreased through the end of 2022, reaching 2.37. Subsequent quarters showed fluctuations, with a peak of 3.00 in June 2024, followed by a decrease to 2.46 by the end of the period.

Overall Trend
From April 2022 to December 2022, the P/S ratio demonstrated a consistent downward trajectory, decreasing from 3.00 to 2.37. This suggests a decreasing valuation relative to sales during this timeframe. The ratio then experienced volatility, oscillating between approximately 2.20 and 3.00 through the remainder of the observation period.
Short-Term Fluctuations
A slight increase in the P/S ratio is observable between October 2023 (2.51) and June 2024 (3.00). This suggests a period of increased investor confidence or a reassessment of the company’s sales potential. However, this increase was not sustained, as the ratio decreased again in subsequent quarters.
Recent Performance
The most recent quarters show a P/S ratio fluctuating around 2.20 to 2.46. The final reported value of 2.46 indicates a slight increase from the prior quarter, but remains below the levels observed in the first half of 2024. This suggests a potential stabilization at a lower valuation relative to sales compared to earlier periods.
Relationship to Share Price and Sales per Share
The P/S ratio’s movements correlate with changes in both share price and sales per share. The decline in the ratio from April 2022 to December 2022 coincided with a decrease in share price and a relatively stable sales per share. The fluctuations observed later in the period reflect the combined impact of changes in both metrics.

In summary, the P/S ratio demonstrates a complex pattern of decline, fluctuation, and potential stabilization. While an initial downward trend was evident, the ratio’s behavior became more variable in later periods, influenced by concurrent changes in share price and sales per share.

AI Ask an analyst for more


Price to Book Value (P/BV)

Pfizer Inc., historical P/BV calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
No. shares of common stock outstanding1 5,686,267,431 5,685,707,552 5,685,550,500 5,685,365,587 5,667,340,414 5,666,990,035 5,666,695,064 5,666,592,898 5,646,778,425 5,646,413,292 5,645,959,570 5,645,307,020 5,619,074,621 5,613,314,537 5,612,351,809 5,610,895,801
Selected Financial Data (US$)
Total Pfizer Inc. shareholders’ equity (in millions) 86,476 92,801 88,695 90,338 88,203 92,286 87,700 92,282 89,014 96,934 99,019 100,970 95,661 92,631 87,208 82,424
Book value per share (BVPS)2 15.21 16.32 15.60 15.89 15.56 16.28 15.48 16.29 15.76 17.17 17.54 17.89 17.02 16.50 15.54 14.69
Share price1, 3 27.10 24.30 24.75 23.87 26.10 27.76 29.74 28.27 27.55 30.82 35.84 38.30 42.30 46.72 49.95 49.45
Valuation Ratio
P/BV ratio4 1.78 1.49 1.59 1.50 1.68 1.70 1.92 1.74 1.75 1.80 2.04 2.14 2.48 2.83 3.21 3.37
Benchmarks
P/BV Ratio, Competitors5
AbbVie Inc. 229.63 102.40 58.73 48.87 36.12 29.97 20.61 20.62 19.68 15.52 16.06 16.76 16.59
Amgen Inc. 22.99 17.91 20.63 24.36 26.61 22.86 28.34 33.25 24.94 17.87 19.19 23.95 35.01 39.30 54.46 138.87
Bristol-Myers Squibb Co. 6.61 5.01 5.06 5.70 6.98 6.60 6.01 5.49 3.35 3.72 3.97 4.46 4.88 4.85 4.90 5.07
Danaher Corp. 2.82 3.05 2.60 2.70 3.00 3.68 3.82 3.51 3.47 2.78 3.65 3.33 3.64 3.77 4.36 4.36
Eli Lilly & Co. 36.91 33.55 33.19 47.74 57.93 56.45 59.24 57.94 65.80 49.10 44.75 33.11 29.36 33.27 34.00 29.75
Gilead Sciences Inc. 8.07 6.85 6.96 6.42 7.36 6.36 5.15 4.61 4.01 4.50 4.63 4.72 4.90 4.63 3.82 3.91
Johnson & Johnson 7.12 5.86 5.20 4.79 5.30 5.69 5.37 5.20 5.48 4.92 5.79 6.00 5.37 6.04 6.01 6.36
Merck & Co. Inc. 5.82 4.04 4.12 4.32 4.99 5.73 6.53 8.00 8.68 6.35 6.96 6.38 6.07 5.63 5.12 5.44
Regeneron Pharmaceuticals Inc. 2.62 2.22 1.98 2.09 2.67 3.14 4.27 3.83 3.96 3.58 3.49 3.52 3.77 3.75 3.21 3.65
Thermo Fisher Scientific Inc. 3.62 4.18 3.46 3.24 4.09 4.36 4.96 4.80 4.57 3.88 4.84 4.99 4.83 4.46 5.47 5.23
Vertex Pharmaceuticals Inc. 6.69 6.18 5.60 7.01 7.24 8.24 8.64 5.71 6.26 5.90 5.98 6.18 5.50 6.18 6.19 5.95

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Data adjusted for splits and stock dividends.

2 Q4 2025 Calculation
BVPS = Total Pfizer Inc. shareholders’ equity ÷ No. shares of common stock outstanding
= 86,476,000,000 ÷ 5,686,267,431 = 15.21

3 Closing price as at the filing date of Pfizer Inc. Quarterly or Annual Report.

4 Q4 2025 Calculation
P/BV ratio = Share price ÷ BVPS
= 27.10 ÷ 15.21 = 1.78

5 Click competitor name to see calculations.


The price to book value (P/BV) ratio exhibited a consistent downward trend over the observed period, beginning April 3, 2022, and continuing through September 28, 2025, before a slight increase at the final observation point. This indicates a decreasing valuation relative to the company’s net asset value. The ratio initially decreased from 3.37 to 1.49 over approximately two years, suggesting investors were willing to pay less for each dollar of net assets. A modest recovery to 1.78 was noted in the final quarter.

Overall Trend
A clear declining trend in the P/BV ratio is evident from April 2022 to September 2025. This suggests a shift in investor sentiment, potentially reflecting concerns about future growth prospects or increased risk perception. The final quarter shows a slight reversal of this trend, but it is too early to determine if this represents a sustained change.
Initial Decline (Apr 3, 2022 – Dec 31, 2022)
The P/BV ratio decreased from 3.37 to 2.48 during this period. This initial decline could be attributed to broader market corrections or company-specific news impacting investor confidence. The rate of decline accelerated in the latter half of the period.
Continued Decrease (Apr 2, 2023 – Sep 28, 2025)
The ratio continued its downward trajectory, reaching a low of 1.49 in September 2025. This phase of the decline was more gradual than the initial decrease, but still consistent. The book value per share remained relatively stable during this period, indicating the primary driver of the P/BV decline was the decreasing share price.
Final Quarter (Dec 31, 2025)
The P/BV ratio experienced a slight increase to 1.78 in the final quarter. This increase coincided with a rise in the share price, while the book value per share decreased. This suggests a renewed, albeit limited, investor optimism.
Book Value Per Share
Book value per share demonstrated a generally increasing trend from April 2022 to October 2022, peaking at 17.89. It then experienced a decline to 15.21 by December 2025. However, the fluctuations in book value per share were less pronounced than those observed in the share price, indicating that changes in investor perception of the company’s value were the dominant factor influencing the P/BV ratio.

In summary, the observed P/BV ratio movements suggest a period of decreasing investor confidence followed by a potential, but tentative, shift in sentiment. Further monitoring is required to ascertain whether the increase in the final quarter represents a sustainable trend.

AI Ask an analyst for more